
==== Front
PLoS One
PLoS One
plos
PLOS ONE
1932-6203
Public Library of Science San Francisco, CA USA

10.1371/journal.pone.0310406
PONE-D-24-02153
Research Article
Biology and Life Sciences
Biochemistry
Bioenergetics
Energy-Producing Organelles
Mitochondria
Biology and Life Sciences
Cell Biology
Cellular Structures and Organelles
Energy-Producing Organelles
Mitochondria
Physical Sciences
Chemistry
Chemical Compounds
Organic Compounds
Carbohydrates
Monosaccharides
Glucose
Physical Sciences
Chemistry
Organic Chemistry
Organic Compounds
Carbohydrates
Monosaccharides
Glucose
Medicine and Health Sciences
Endocrinology
Endocrine Physiology
Insulin Resistance
Biology and Life Sciences
Physiology
Endocrine Physiology
Insulin Resistance
Biology and Life Sciences
Physiology
Electrophysiology
Membrane Potential
Biology and Life Sciences
Biochemistry
Bioenergetics
Energy-Producing Organelles
Mitochondria
Mitochondrial Membrane
Biology and Life Sciences
Cell Biology
Cellular Structures and Organelles
Energy-Producing Organelles
Mitochondria
Mitochondrial Membrane
Medicine and Health Sciences
Endocrinology
Diabetic Endocrinology
Insulin
Biology and Life Sciences
Biochemistry
Hormones
Insulin
Biology and Life Sciences
Cell Biology
Oxidative Stress
Biology and Life Sciences
Anatomy
Musculoskeletal System
Muscles
Skeletal Muscles
Medicine and Health Sciences
Anatomy
Musculoskeletal System
Muscles
Skeletal Muscles
Elucidating the effect of drug-induced mitochondrial dysfunction on insulin signaling and glucose handling in skeletal muscle cell line (C2C12) in vitro
Drug-induced mitochondrial toxicity and insulin resistance
https://orcid.org/0009-0006-9523-9314
Kuretu Auxiliare Conceptualization Data curation Formal analysis Investigation Visualization Writing – original draft 1
https://orcid.org/0000-0002-8613-2543
Mothibe Mamosheledi Supervision Validation Writing – original draft 1
Ngubane Phikelelani Supervision Validation Writing – review & editing 2
https://orcid.org/0000-0001-5894-8935
Sibiya Ntethelelo Conceptualization Data curation Funding acquisition Project administration Supervision Validation Writing – review & editing 1 *
1 Pharmacology Division, Faculty of Pharmacy, Rhodes University, Makhanda, South Africa
2 School of Medical Sciences and Laboratory Medicine, University of KwaZulu-Natal, Durban, South Africa
Kanzaki Makoto Editor
Tohoku University, JAPAN
Competing Interests: The authors have declared that no competing interests exist

* E-mail: n.sibiya@ru.ac.za
17 9 2024
2024
19 9 e031040616 1 2024
31 8 2024
© 2024 Kuretu et al
2024
Kuretu et al
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Efavirenz, tenofovir, rifampicin, simvastatin, lamotrigine and clarithromycin are known potential mitochondrial toxicants. Mitochondrial toxicity has been reported to disrupt the chain of events in the insulin signalling pathway. Considering the upward trajectory of diabetes mellitus prevalence, studies which seek to uncover probable risk factors for developing diabetes should be encouraged. This study aimed to evaluate the intracellular mechanisms leading to the development of insulin resistance in the presence of various conventional pharmacological agents reported as potential mitochondrial toxicants in skeletal muscle cell line. Differentiated C2C12 preparations were exposed to multiple concentrations of efavirenz, tenofovir, rifampicin, simvastatin, lamotrigine, and clarithromycin, separately. Glucose handling was evaluated by observing the changes in insulin-stimulated glucose uptake and assessing the changes in GLUT4 translocation, GLUT4 expression and Akt expression. The changes in mitochondrial function were evaluated by assessing mitochondrial membrane integrity, cellular ATP production, generation of intracellular reactive oxygen species, expression of tafazzin and quantification of medium malonaldehyde. Insulin stimulated glucose uptake was perturbed in C2C12 pre-treated with potential mitotoxicants. Additionally, ATP synthesis, alterations in mitochondrial membrane potential, excessive accumulation of ROS and malonaldehyde were observed in the presence of potential mitotoxicants. Particularly, we observed suppression of proteins involved in the insulin signalling pathway and maintenance of mitochondrial function namely GLUT4, Akt and tafazzin. Mitochondrial toxicants can potentially induce insulin resistance emanating from mitochondrial dysfunction. These new findings will contribute to the understanding of underlying mechanisms involved in the development of insulin resistance linked to mitochondrial dysfunction.

National Research Foundation TTK220318196 https://orcid.org/0000-0001-5894-8935
Sibiya Ntethelelo This study was supported by National Research Foundation: TTK220318196 awarded to NS. https://www.nrf.ac.za/ The funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Data AvailabilityAll relevant data are within the manuscript and its Supporting Information files
Data Availability

All relevant data are within the manuscript and its Supporting Information files
==== Body
pmcIntroduction

Diabetes mellitus is a chronic metabolic disorder characterised by glucose homeostasis impairment resulting in hyperglycaemia [1–23]. The prevalence of type 2 diabetes (T2DM) is continuously increasing worldwide. According to the International Diabetes Federation (IDF), more than 90% of individuals with diabetes have T2DM [2, 3]. T2DM is driven by genetic, socio-economic, demographic and environmental factors. The aetiology of T2DM involves pancreatic ß cell dysfunction and insulin resistance in insulin-sensitive tissues such as hepatocytes, adipocytes and skeletal muscle [4–6]. Insulin resistance is associated with the accumulation of free fatty acids, elevated hepatic glucose production and decreased glucose uptake in insulin-sensitive tissues [4, 7, 8]. Compelling evidence suggests that mitochondrial impairment can potentially contribute to the development of insulin resistance [9–11]. Mitochondria play a significant role in cellular life, stress responses and death. Various studies have linked mitochondrial impairment with the initiation and propagation of inflammatory responses [12, 13]. Mitochondria have attracted the attention of researchers for decades and their importance in cellular function and energy homeostasis has spawned much interest in metabolic diseases such as a variety of cancers, cardiovascular diseases, and neurodegenerative disorders such as Parkinson’s and Alzheimer’s and T2DM [9, 12, 14]. Importantly, it has been suggested that mitochondrial dysfunction is associated with insulin resistance in skeletal muscle and other tissues such as the liver and adipose. Insulin resistance is associated with depleted levels of mitochondrial oxidative enzymes, ATP levels and abnormal mitochondrial morphology [9–11]. However, the relationship between mitochondrial dysfunction and the development of insulin resistance is not yet fully elucidated. Insistent evidence suggests that improving mitochondrial function can serve as a positive therapeutic tool in enhancing insulin sensitivity [10, 15]. Various drug classes have been reported to potentially induce insulin resistance ascribed to mitochondrial dysfunction. Drug classes such as statins, anti-diabetics, anti-epileptics, NSAIDs, anti-depressants, and certain antibiotics have been identified to induce mitochondrial toxicity and potentially cause insulin resistance however this hypothesis is not yet elucidated [15].

This study aimed to characterize the effect of selected potential mitotoxic drugs on glucose homeostasis in skeletal muscle cell lines in vitro. Skeletal muscle cells were utilized as they are the primary site of insulin-stimulated glucose uptake and play an essential role in maintaining glucose homeostasis [16–18]. Tenofovir, efavirenz, rifampicin, lamotrigine, clarithromycin, and simvastatin were the selected drugs of choice. These drugs have been indicated as potential mitochondrial toxicants that exert adverse effects on various biochemical pathways including the insulin signalling pathway [15, 19]. We envisaged that assessing changes in glucose uptake, GLUT 4 expression, GLUT 4 translocation, relative expression of Akt and tafazzin, ATP synthesis, oxidative stress status and mitochondrial membrane polarisation state would elucidate a direct link between drug-induced mitochondrial toxicity and impaired insulin sensitivity.

Materials and methods

Chemicals

The following chemicals, drugs and assay kits were purchased from Sigma-Aldrich (USA). Dulbecco’s modified eagle’s medium (DMEM), fetal bovine serum (FBS), and penicillin-streptomycin (USA, ATP bioluminescence Kit, Fluorometric Intracellular ROS Kit, Bovine Serum albumin (BSA), Tris HCL, Triton X100, Rabbit polyclonal anti-phospho-Akt antibody, Anti-Akt2 antibody produced in rabbit, GLUT4 antibody, Citric acid, Simvastatin, Clarithromycin, Rifampicin, Tenofovir, Efavirenz, Lamotrigine, 3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), Insulin, sodium phosphate dibasic (Na2HPO4), Monopotassium phosphate (KH2PO4), Sodium chloride (NaCl), Potassium chloride (KCl), Sodium hydroxide (NaOH), Hydrochloric acid (HCl), Tween 20, Paraformaldehyde, Dimethyl sulfoxide (DMSO), 3,3′,5,5′-Tetramethylbenzidine (TMB), Horseradish peroxidase (HRP), Hydrogen peroxide (H2O2), Trypan blue, Butanol, Ethanol Phosphoric acid (H3PO4), 2- Thiobarbituric acid (TBA), Butylated hydroxytoluene (BHT), 0.05% Trypsin–EDTA (ThermoFisher Scientific).

Methods

Skeletal muscle cell culture and differentiation

Assays were performed using skeletal muscle (C2C12), which were cultured in tissue culture flasks (T25 and T75) in the presence of Dulbecco’s modified eagle’s medium (DMEM) supplemented with 1% penicillin-streptomycin and 10% foetal bovine serum (FBS) in a humidified incubator with 5% CO2 at 37°C. After the cells had reached approximately 80% confluence, they were trypsinized and passaged into new flasks until ready for seeding.

Cell viability

To evaluate cell viability, the 3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was performed in the presence of selected drugs. C2C12 cells were seeded into 96 well-plate clear bottom tissue culture plates at a density of (4.65 ×104) until they reached approximately 80% confluence. The cells were exposed to different concentrations (25–400μM) of the drugs. After 24 hours, MTT solution (100μM) was added to each well, and the plate was incubated for three hours in the dark. Thereafter, DMSO (100μM) was added, and the plate was incubated for ten minutes. The absorbance was measured at 570nm using a UV-VIS Spectrophotometer. The cell viability was calculated as follows: Percentageviability(%)=AbsorbanceofsampleAbsorbanceofcontrol×100

NB: The cell viability study demonstrated that the ideal concentrations for further biochemical analysis were (25–100 μM).

Estimation of cellular glucose uptake

C2C12 were seeded at a density of (4.35 ×104) in 24 well plates and were allowed to adhere. Thereafter, the myoblasts were differentiated into myotubes by switching normal medium to DMEM supplemented with 0.2% FBS and 1% penicillin-streptomycin for three days. The medium was replaced daily until differentiated multinucleated myotubes were observed under a microscope. The myotubes preparation were then preincubated at 37°C for 24 hrs with different drug concentrations (25–100μM). After 24 hrs the culture medium was aspirated from the well and washed with Phosphate-Buffered Saline (200μM) three times. DMEM (200μL) supplemented with insulin (0.05μ/ml) was transferred into each well. The plate was incubated for a further 24 hours after which the medium glucose concentration was measured using an Accu-Check Performa glucometer. The cell preparation exposed to drug treatments but not treated with insulin served as a negative control, and preparations only treated with insulin served as a positive control. The assay was performed in triplicate. The estimation of glucose uptake was determined using the following formula: Glucoseuptake(%)=MediumGlucose(T0)-Mediumglucose(T24)Mediumglucose(T0)×100

In-cell ELISA

C2C12 cells were seeded at a density of (4.97×104) in 96 well plates. After the cells had reached approximately 80% confluence, they were preincubated at 37°C for 24 hrs with different drug concentrations (25–100 μM) in DMEM. After 24 hours, the medium was aspirated, and paraformaldehyde (8%, 100 μL) was added to each well for fixation. The plate was incubated for 15 minutes at room temperature whilst shaking with a microplate shaker at 300rpm. The paraformaldehyde was aspirated, and each well was washed four times using PBS (200 μL) followed by the addition of 2X permeabilization buffer (Triton X-100) (200 μL) into each well. Thereafter, the plate was incubated for 30 minutes at room temperature whilst shaking at 300 rpm. After 30 mins, the permeabilization buffer was aspirated from the wells and a blocking buffer (1X BSA, 200 μL) was added and incubated at room temperature for 2 hours whilst shaking the plate. Thereafter, the blocking buffer was aspirated and the relevant primary antibody (GLUT 4, Akt, Tafazzin) (100 μL) was added, separately. The plate was incubated at 4°C overnight. After incubation, the primary antibody was aspirated, and the plate was washed three times using wash buffer (250 μL). Thereafter, 100 μL of a secondary antibody (anti-rabbit IgG) with specificity to the primary antibody was added to each well. The plate was incubated at room temperature for 2 hours whilst shaking. After incubation, the plate was washed four times using wash buffer (250 μL) after which the horseradish peroxidase substrate (HRP) (100 μL)) was transferred into each well and incubated for 30 minutes whilst shaking. To stop the reaction, HCL (100 μL, 0.1M) was added into each well and absorbance was read at 450 nm using a spectrophotometer. The assays were performed in triplicate. To determine GLUT 4 expression, the same in-cell ELISA procedure was applied omitting the cell permeabilization step. The relative expression or translocation was calculated as follows: Relativeexpression(%)=AbsorbanceoftreatedwellsAbsorbanceofcontrolwells×100

Thiobarbituric acid reactive substances assay (TBARS)

A TBARS assay was performed by modifying a method developed by Potter et al to quantify malonaldehyde concentration (MDA) [20]. A medium sample (400 μL) was collected from treated C2C12 cells was transferred into a test tube containing 200 μL of 2% phosphoric acid (H3PO4). The homogenate was separated into 2 test tubes with each test tube receiving an equal volume (300 μL). Then 800 μL of TBA/BHT (TBA 0.67% w/v and BHT 0.01% w/v) solution was added into one test tube (sample test) and HCL (400 μL of 3 Mm) was added into the second test tube (blank). Both solutions were heated at 95°C for 20 minutes and were allowed to cool to room temperature. Butanol (1.5 mL) was added to the cooled samples. The sample solution was vortexed for 1 minute to ensure rigorous mixing and then allowed to settle until 2 distinguished liquid phases were observed. The butanol phase (top layer) was transferred to Eppendorf tubes and centrifuged at 13249 x g in a centrifuge for 15 minutes. The samples were aliquoted into wells of a 96-well microtiter plate in triplicates and the absorbance was read at 532 nm (reference λ 600 nm) using a microplate reader. The absorbance from these wavelengths was used to calculate the concentration of MDA using the following formula which applies the Beer-Lambert law: MDAconcentration=Finalabsorbance−BlankMDAextinctioncoefficient156mmol−1

ATP bioluminescence assay

An ATP bioluminescence assay was performed according to the manufacturer’s protocol (ATP Bioluminescence Assay Kit CN: FLAA-1KT, Saint Louis, USA) with the following adjustments. C2C12 cells were seeded in a solid black 96 well plate at a density of (4.23×104) and incubated for 24 hours to allow the cells to adhere. Thereafter, the cells were treated with the drugs (clarithromycin, efavirenz, tenofovir, lamotrigine, simvastatin, and rifampicin) at different concentrations (25, 50 and 100 μM) for 24 hours. The control wells consisted of untreated cells. The medium was removed after 24 hours and luciferase (50μL) and luciferin (50μL) were added into each well. The plate was incubated at room temperature for 15 minutes and protected from light. The luminescence signal was detected using a microplate reader.

Intracellular ROS assay

To detect ROS, a cell permeable reduced MitoTracker Red CM-H2XROS dye was used, and it produces fluoresces upon oxidation. An intracellular ROS fluorescence assay was performed according to the manufacturer’s protocol (Fluorometric Intracellular ROS Kit CN: MAK143-1KT, Saint Louis, USA) with the following adjustments: Briefly, C2C12 cells were seeded in a solid black 96 well plate at a density of (4.23 × 104) and incubated for 24 hours to allow the cells to adhere to the culture plates. The cells were treated with the drugs (clarithromycin, efavirenz, tenofovir, lamotrigine, simvastatin, and rifampicin) in concentrations of 25, 50 and 100 μM for 24 hours. The control wells consisted of untreated cells. Then 50 μL of the master reaction mix (ROS detection reagent) was pipetted into each well. The plate was incubated in a humidified incubator for one hour. The absorbance was set at an excitation wavelength of 490 nm and an emission wavelength of 525 nm using a microplate reader.

Mitochondrial membrane potential assay

Mitochondrial inner membrane electrochemical potential changes were detected according to the manufacturer’s protocol (Mitochondrial staining kit, CN: CS0390, Saint Louis, USA) with minor modifications. C2C12 cells were seeded in a solid black 96 well plate at a density of (4.23×104) and incubated for 24 hours to allow the cells to adhere to the culture plates. The cells were treated with the drugs (clarithromycin, efavirenz, tenofovir, lamotrigine, simvastatin and rifampicin) at different concentrations (25, 50 and 100 μM) for 24 hours. The control had untreated wells. The growth medium was aspirated from the wells and the cells were overlayed with 50 μL of staining solution (JC-1 dye). The plate was incubated for 20 minutes at 37°C. Fluorescence was determined at an excitation wavelength of 490nm and an emission wavelength of 525nm.

Statistical analysis

Results were represented as mean ±SD. All the statistical analyses were performed using Graph Pad Prism (version 8.0.2). Assays were performed in triplicate and the mean was used for statistical analysis. Statistical significance was determined using the ordinary one-way ANOVA test followed by Dunnett’s post hoc test to compare the treatments and control. Significance was defined a priori as a *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.

Results

Cell viability

A cytotoxicity study of mitochondrial toxicants was performed in C2C12 at concentrations of 25, 50, 100, 200 and 400 μM as displayed in Fig 1. All six drugs showed a significant statistical difference from the control at different concentrations except simvastatin and tenofovir at 25 μM and clarithromycin at 25 and 50 μM. The cell viability decreased as the concentration of the drugs increased.

10.1371/journal.pone.0310406.g001 Fig 1 Cell viability study after treating C2C12 with potential mitotoxicants for 24 hours at various concentrations (25–400μM).

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at (p < 0.05), (***) p<0.001, (****) p<0.0001.

Glucose utilization

The percentage glucose uptake was estimated after treating C2C12 with mitochondrial toxicants (efavirenz, tenofovir, rifampicin, clarithromycin, simvastatin, lamotrigine) at different concentrations (25, 50, 100 μM) for 24 hours. The glucose uptake estimation is displayed in Fig 2. The insulin- treated group had a higher glucose uptake compared to the non-treated control. All the six drugs showed a concentration-dependent decrease in glucose uptake in comparison to the control. All the six drugs and insulin pre-treated group showed a significant statistical difference from the control at different concentrations except simvastatin and rifampicin at 25 μM and clarithromycin at 25 and 50 μM.

10.1371/journal.pone.0310406.g002 Fig 2 Percentage glucose uptake estimation after treating C2C12 with potential mitotoxicants at 25, 50 and 100 μM for 24 hours.

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at p < 0.05, (**) p < 0.01, (***) p < 0.001, (****) p < 0.001.

GLUT4 translocation

Fig 3 displays the relative percentage of the GLUT4 translocation to the plasma membrane. GLUT 4 translocation gradually decreased in the presence of tenofovir, rifampicin, clarithromycin and simvastatin in comparison to the control. An acute increase in GLUT4 translocation was observed in C2C12 pre-treated with efavirenz and lamotrigine. There was a significant statistical difference in all six drugs at different concentrations except efavirenz at 50 and 100 μM and clarithromycin at 25 μM.

10.1371/journal.pone.0310406.g003 Fig 3 Relative GLUT 4% translocation after 24 hours of exposure to potential mitotoxicants (25, 50, 100 μM).

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at (p < 0.05), (**) p<0.01, (***) p<0.001, (****) p<0.0001.

GLUT 4 expression

Fig 4 indicates a decreased expression of GLUT4 protein in the presence of tenofovir, rifampicin, clarithromycin and simvastatin. An acute increase in GLUT4 expression was observed in C2C12 treated with efavirenz and simvastatin between concentrations of 25–100 μM. All six drugs showed a significant statistical difference from the control at different concentrations except for rifampicin at 25 and 50 μM.

10.1371/journal.pone.0310406.g004 Fig 4 Relative GLUT4% expression after 24 hours of exposure to potential mitotoxicants (25, 50, 100 μM).

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at (p < 0.05), (**) p<0.01, (***) p<0.001, (****) p<0.0001.

Akt expression

Fig 5 displays the relative percentage expression of Akt protein in C2C12 treated with mitotoxicants. As depicted in Fig 5, a decrease in Akt expression was observed with except in cells treated with lamotrigine where Akt expression was elevated in a directly proportional manner. All six drugs showed a significant statistical difference from the control at different concentrations except for simvastatin at 25 μM.

10.1371/journal.pone.0310406.g005 Fig 5 Relative Akt % expression after 24 hours of exposure to potential mitotoxicants (25, 50, 100 μM).

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at (p < 0.05), (**) p< 0.01, (***) p< 0.001, (****) p< 0.0001.

Mitochondrial tafazzin expression analysis

Fig 6: displays the relative percentage expression of mitochondrial tafazzin protein in C2C12 treated with potential mitotoxicants. A decrease in tafazzin expression is observed in C2C12 pre-treated with simvastatin, lamotrigine, rifampicin, clarithromycin, efavirenz and tenofovir. All six drugs showed a significant statistical difference from the control at different concentrations except for (rifampicin, efavirenz) at 25 μM and (clarithromycin, lamotrigine) at 25 and 50 μM.

10.1371/journal.pone.0310406.g006 Fig 6 Relative tafazzin protein % expression after 24 hours of exposure to potential mitotoxicants (25, 50, 100 μM).

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at (p < 0.05), (**) p<0.01, (***) p<0.001.

Intracellular reactive oxygen species

Fig 7 displays a significant increase in fluorescence intensity in the presence of simvastatin, lamotrigine, clarithromycin and efavirenz indicating increased oxidation of MitoTracker Red by ROS. However, rifampicin and tenofovir acutely increased the fluorescence intensity. A directly proportional relationship between drug concentration and fluorescence intensity was observed. There was no significant statistical difference between tenofovir and the control at p < 0.05. All the remaining drugs showed a significant statistical difference from the control at different concentrations except for clarithromycin at 50 μM and lamotrigine at 25 μM.

10.1371/journal.pone.0310406.g007 Fig 7 Intracellular ROS production after 24 hours of exposure to potential mitotoxicants (25, 50, 100 μM).

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at (p < 0.05), (**) p < 0.01, (***) p < 0.001, (****) p < 0.0001.

Lipid peroxidation

Fig 8 indicates a dose-dependent increase in the medium MDA in the presence of five drugs except for tenofovir which gradually decreased the MDA concentration. There was a significant statistical difference from the control in all the drugs at different concentrations except for rifampicin at 25 μM.

10.1371/journal.pone.0310406.g008 Fig 8 Estimated medium MDA concentration after 24 hours of exposure to potential mitotoxicants at 25, 50 and 100 μM.

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at (p < 0.0), (**) p < 0.01, (***) p < 0.001, (****) p < 0.0001.

Mitochondrial membrane potential

Fig 9 depicts an acute reduction in mitochondrial membrane potential observed in the presence of rifampicin and simvastatin. However, efavirenz and lamotrigine slightly increased the membrane potential. There was a significant increase in mitochondrial membrane potential in the presence of tenofovir and clarithromycin. The control consisted of untreated cells. There was no significant statistical difference between tenofovir and the control at p < 0.05. All the remaining drugs showed a significant statistical difference from the control at different concentrations except for (tenofovir and rifampicin) at 25 μM and simvastatin at 50 and 100 μM.

10.1371/journal.pone.0310406.g009 Fig 9 Mitochondrial membrane potential was evaluated after 24 hours of exposure to potential mitotoxicants (25, 50, 100 μM).

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at (p < 0.05), (**) p < 0.01, (***) p < 0.001, (****) p < 0.0001.

ATP bioluminescence

A commercially available bioluminescence kit was used to determine the ATP content. The luminescence signal was directly proportional to the concentration of ATP produced as displayed in Fig 10. rifampicin, simvastatin and clarithromycin significantly increased the concentration of ATP. Fig 10 shows a decrease in ATP production in the presence of lamotrigine, tenofovir. All six drugs showed a significant statistical difference from the control at different concentrations except simvastatin at 25 μM and clarithromycin at (25 and 50 μM).

10.1371/journal.pone.0310406.g010 Fig 10 Cellular ATP production after 24 hours of exposure to potential mitochondrial toxicants (25, 50, 100 μM).

The data are represented as mean ± SD represented with error bars, (n = 3), and the asterisk (*) represents the statistical difference between the test compounds and the control at p < 0.05, (**) p < 0.01, (***) p < 0.001, (****) p < 0.0001.

Discussion

As alluded to, mitochondrial dysfunction has been reported to be one of the central causes of insulin resistance and its associated complications [10–12, 14]. Hence, it is imperative to perform studies to elucidate the link between drug-induced mitochondrial toxicity and the development of insulin resistance. In our study, we investigated six pharmacological agents that belong to different drug classes, particularly NNRTIs, NRTIs, antibiotics, statins, and anti-epileptics. C2C12 is an insulin-sensitive cell line that serves a beneficial role in insulin resistance mechanisms in vitro studies [16–18]. Skeletal muscle metabolism is mediated by insulin, especially glucose uptake and synthesis of glycogen related to the PI3K/Akt signalling pathway [21]. Stimulation of the skeletal muscle by insulin activates a series of phosphorylation and P13K/Akt which culminates into GLUT 4 translocation, leading to glucose uptake [16, 22, 23].

Efavirenz is an extensively prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) however, it has been associated with the development of dysglycaemia and dyslipidaemia [24–26]. Efavirenz is administered as a single dose of 600mg in adults resulting in a therapeutic plasma concentration between 3.17 to 12.67 μM [27]. The aetiology of these metabolic effects remains unclear however, it has been reported that it is associated with mitochondrial toxicity [27, 28]. Blas-García and colleagues 2010 observed that clinical concentrations of efavirenz in hepatic cells acutely inhibited mitochondrial function resulting in bioenergetic stress. The mechanism of action involved the accumulation of lipids in the cytoplasm mediated by AMPK activation [28]. However, the coadministration of efavirenz with abacavir and lamivudine alters some of its mitochondrial effects [28, 29]. Furthermore, a cohort study conducted by Karamchand et al. in South African adults observed that an ART regimen consisting of efavirenz is associated with a higher risk of developing new-onset diabetes compared to a regimen containing nevirapine. Our observations suggest that exposure of C2C12 to efavirenz halts insulin sensitivity as demonstrated by poor glucose uptake and reduced expression of insulin signalling pathway proteins. This impairment of insulin signalling corroborated with increases in oxidative stress status as evidenced by the increase in intracellular ROS and MDA. Our study did not observe a significant change in ATP production and mitochondrial membrane potential. This implies that efavirenz possibly induces mitochondrial impairment through excessive generation of ROS, decreased tafazzin expression and the accumulation of lipid peroxides. To address whether there is a correlation between the generation of mitochondrial ROS and the development of insulin resistance in vivo, Anderson and colleagues administered a potent antioxidant peptide, SS31 which specifically targets the mitochondria [30]. The evidence suggested that the coadministration of SS31 in rats that were on a 6-week high-fat diet reduced the emission of mitochondrial H2O2 by 50%. The emitting potential of mitochondrial ROS was also stabilized, and the development of insulin resistance was mitigated. Efavirenz has also been reported to inhibit the secretion of adiponectin, a hormone involved in insulin sensitization and fatty acid breakdown. Taken together, these findings underscore the significance of mitochondrial dysfunction induced by efavirenz in the development of insulin resistance in insulin-sensitive tissues.

Various clinical trials have suggested that tenofovir disoproxil fumarate (TDF) used as pre-exposure prophylaxis (PrEP) to prevent HIV infection either in combination with emtricitabine (FTC) or not, has a good safety profile [31, 32]. TDF has shown favourable metabolic profiles, however, evaluating the specific adverse events induced by TDF/FTC on isolated metabolic parameters is challenging [33]. This is because various factors affect lipids and body composition including the HIV infection and the host response to the infection. Additionally, drugs that are part of the ARV regimen are likely to alter the pharmacokinetic properties of tenofovir. Previous studies suggested that mitochondria are subcellular target organelles of tenofovir toxicity [34–36]. In this study, the glucose utilization slightly decreased as the concentration of tenofovir increased, this can be linked to the decrease in GLUT 4 translocation and expression observed in Figs 3 and 4. These observations suggest that GLUT 4 expression and translocation can potentially be inhibited by tenofovir resulting in decreased insulin-stimulated glucose uptake. Additionally, the expression of Akt gradually decreased as the concentration of tenofovir increased as indicated in Fig 5. Thus, the downregulation in insulin-stimulated glucose uptake can be due to disruption of the chain of events in the insulin signalling pathway. Interestingly, tenofovir slightly decreased the expression of tafazzin, a non-specific phospholipid–lysophospholipid transacylase protein which is responsible for cardiolipin synthesis and remodelling [37]. Various in vivo studies reported that tafazzin deficiency leads to reduced cardiolipin concentration and partially dissociates protein super complexes of the inner mitochondrial membrane [38–41]. Compelling evidence suggests that tafazzin-deficient mitochondria exhibit functional modifications such as increased oxidative stress, partial uncoupling, and reduced membrane potential [38, 42, 43]. These observations insinuate that tenofovir induced oxidative stress and possibly depleted the expression of tafazzin thus, halting oxidative phosphorylation as evidenced by the diminished ATP production.

Rifampicin is a macrocyclic antibiotic which widely prescribed as a component of a multidrug regimen for tuberculosis [44]. In this study, we observed that rifampicin exhibited a dose-dependent reduction in insulin-stimulated glucose uptake. Garg et al conducted an in vivo study using mice models and observed that rifampicin improved glucose homeostasis and reduced diabetic complications by inhibiting the formation of advanced glycation end-products in mice [45]. However, in our study rifampicin gradually decreased glucose uptake associated with reduction of GLUT 4 expression and translocation. Studies have reported that rifampicin exhibited antioxidant properties by elevating p-AMPKα levels during a state of oxidative stress [46]. Furthermore, Liang et al observed that rifampicin preserved mitochondrial function through the reduction of ROS production in rotenone induced models [47]. On the contrary, Li et al reported a reduction in mitochondrial membrane integrity, accumulation of ROS and a decrease in ATP synthesis in human hepatocytes exposed to rifampicin [48]. In our study, an acute increase in the generation of ROS was observed. However, the significant increase in MDA production and loss of mitochondrial membrane potential can be attributed to perturbed mitochondrial function. Additionally, oxidative stress has been associated with poor glucose uptake through suppression of Akt. Various studies have closely linked excessive generation of ROS and mitochondrial dysfunction in the presence of rifampicin [49–51]. Considering that tafazzin expression acutely decreased, this could be an indication of mitochondrial dysfunction. Accordingly, it is plausible that the modification in mitochondrial oxidative metabolism contributes to the observed disruptions in insulin sensitivity.

The macrolide clarithromycin is used to treat an array of bacterial infections [52, 53]. Our study demonstrated that exposure of clarithromycin to C2C12 cells induced oxidative stress which could partly explain mitochondrial hyperpolarisation observed. ROS can lead to mitochondrial injury through mitochondrial DNA injury and damage to mitochondrial proteins including OXPHOS and transporter proteins [12, 19, 49]. Oxidative stress is a highly sensitive indicator of alterations in mitochondrial membrane integrity. An increase in the generation of ROS has been implicated in the onset of mitochondrial impairment and some studies have reported ROS as the primary cause of diabetic complications [54]. Hyperglycaemia is associated with excessive generation of ROS [4, 8]. These observations suggest that clarithromycin potentially induces insulin resistance through oxidative stress and altering mitochondrial membrane integrity. Furthermore, the ROS can also have a detrimental effect on insulin signalling proteins thus leading to a decrease in Akt expression and GLUT 4 translocation and expression. Various studies reported that increased generation of mitochondrial ROS occurs via inhibition of mitochondrial ETC at complex III [55–57]. In agreement with these observations, tafazzin was significantly reduced which can allude to a decrease in the function of OXPHOS.

There have been reports of an existing relationship between the use of antipsychotics and the development of T2DM [15, 58]. However, the exact mechanism of action is not yet fully elucidated. Previous studies proposed mechanisms for antipsychotic-induced DM such as weight gain and decreased insulin secretion in pancreatic ß cells by promoting cellular apoptosis [58–60]. Our study observed a slight decrease in insulin-stimulated glucose uptake as the concentration of lamotrigine increased which could be attributed to other affected GLUT transporters considering that GLUT4 translocation was increased. In addition, Akt expression increased as the concentration of lamotrigine increased. Figs 7 and 8, suggest that lamotrigine induces oxidative stress. Various studies established that MDA is generated during lipid peroxidation and is a biomarker of oxidative stress. Lipids and lipoproteins are the major peroxidation targets in biological membranes thus, lipid peroxidation assays are commonly used to estimate oxidative status in vitro [20, 61, 62]. Houstis and colleagues reported that the generation of ROS in cultured 3T3-L1 adipocytes preceded insulin resistance and ROS scavenging improved insulin sensitivity [63]. The evidence suggested that ROS is the primary cause of insulin resistance. These findings suggested that the potential mechanism for lamotrigine-induced insulin sensitivity dysregulation is elevated levels of oxidative stress.

Simvastatin, a cholesterol-lowering agent has been recognised to impair insulin sensitivity [64–67]. Indeed, our study demonstrated impaired insulin signalling. Previous studies reported that the mitochondria play a significant role in statin-induced myopathies due to mitochondrial ubiquinone (CoQ10) depletion [68–70]. Interestingly, we observed a dose-dependent increase in cellular ATP synthesis in the presence of simvastatin. However, there was a slight increase in the maintenance of mitochondrial membrane potential as the dose increased. Fig 9 displays the effectiveness of simvastatin in maintaining MMP. These observations insinuate that the increase in ATP production observed is due to the effectiveness of simvastatin in maintaining MMP. Mitochondrial membrane potential maintenance is essential for preserving cellular homeostasis and ATP production [71]. The protective effect exhibited by simvastatin may be dependent on the mitoKATP channels. Steven P Johns et al suggested that the protective effect of simvastatin deteriorates when the mitoKATP channel is blocked in cardiac myocytes [72]. An increase in the generation of intracellular ROS and MDA was observed as displayed in Figs 8 and 9 indicating an increase in oxidative stress. Cumulatively, these observations suggest that the presumed diabetogenic effect of simvastatin is dose-dependent. The use of an isolated skeletal muscle system proposes the potential effect of simvastatin to directly exert a protective effect in the absence of other cell types. Additionally, the evidence proposing a link between the use of simvastatin and the development of T2DM varies among populations. For instance, an increase in T2DM incidence was observed in geriatric patients and prediabetic individuals [73].

Collectively, this study may further consolidate links between drug-induced mitochondrial toxicity and impaired insulin sensitivity as illustrated in Fig 11. Using different drug classes could further suggest that mitochondrial toxicity emanates from a wide range of conventional agents. For these reasons, our stride to curb diabetes should consider acknowledging some conventional pharmacotherapies indicated for different ailments as risk factors for developing insulin resistance. The varying observations with previous studies can be ascribed to varying cell culturing conditions, particularly experimental parameters and/or remodelling approaches. However, this study drew its conclusion from in vitro models thus, some of the observations vary from clinical manifestations reported. Most in vitro models of human skeletal muscles lack a three-dimensional structure and mechanical guidance cues found in vivo in native tissues [74–77]. They rely on the conventional two-dimensional (2D) cell cultures, which leads to the detachment of myotubes after a few days of myoblast fusion. Therefore, there is limited cell maturation and cessation in long-term experimental studies. Advanced 3D human skeletal tissue models improve upon 2D models thus allowing long-term culture and the cells can undergo functional tests such as measuring oxygen consumption, calcium handling, and metabolite production. An appreciation of the challenges and complexities associated with such measurements is crucial to avoid common experimental and analytical errors. Nevertheless, our findings do not preclude other probable mechanisms that mitochondrial toxicants can induce insulin resistance. Therefore, there is a need for further studies which seek to refine mechanisms associated with these mitotoxic agents in a context of disturbing glucose handling.

10.1371/journal.pone.0310406.g011 Fig 11 An illustrative scheme of a proposed mechanism linking mitochondrial dysfunction induced via potential mitotoxicants and the development of insulin resistance.

Excessive production of ROS and MDA is observed in the presence of all the selected potential mitotoxicants resulting in an oxidative stress state. Tafazzin expression decreased suggestively indicating a depletion in cardiolipin content resulting in disrupted mitochondrial membrane permeability. Mitochondrial dysfunction results in diminished ATP production and disrupted mitochondrial membrane potential. The oxidative stress state and modified MMP disrupt oxidative phosphorylation in the insulin signalling pathway and affect the translocation and expression of proteins involved in the chain of events. Thus, mitochondrial dysfunction leads to increased ROS production and MDA, decreased TAZ expression and altered MMP resulting in insulin resistance in skeletal muscle.

Conclusion

In summary, our observations suggest that mitotoxicants can potentially induce insulin resistance emanating from mitochondrial dysfunction. However, further studies are required to fully define the clinical implications of mitochondrial dysfunction on the development of insulin resistance as demonstrated in our in vitro study.

Supporting information

S1 Data (XLSX)

10.1371/journal.pone.0310406.r001
Decision Letter 0
Kanzaki Makoto Academic Editor
© 2024 Makoto Kanzaki
2024
Makoto Kanzaki
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version0
16 Jul 2024

PONE-D-24-02153Elucidating the effect of drug-induced mitochondrial dysfunction on insulin signalling cascade and glucose handling in C2C12 cell line in vitroPLOS ONE

Dear Dr. Sibiya,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

First and foremost, I apologize for the delay in responding. Your manuscript was sent to over 20 potential referees, but it proved quite challenging to obtain responses from two reviewers. Their comments are appended below.

Both reviewers found your study to be of significant interest; however, they have several concerns that need to be addressed before we can proceed further. In particular, one reviewer suggests additional experiments regarding the effects of drugs on insulin-treated myotubes, which I concur with.

Please submit your revised manuscript by Aug 30 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Makoto Kanzaki, Ph.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Additional Editor Comments:

First and foremost, I apologize for the delay in responding. Your manuscript was sent to over 20 potential referees, but it proved quite challenging to obtain responses from two reviewers. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: GENERAL COMMENTS

The study tested the effects of several compounds to alter mitochondrial function and induce insulin resistance. There were some English/grammar issues that a thorough re-read can fix. Although the approaches were appropriate and the data appeared to be carefully obtained, the significant issue was that the drug studies were not completed on insulin treated myotubes.

SPECIFIC COMMENTS

Page 17, Results, line 6-7. The sentence “However, efavirenz, lamotrigine and rifampicin (100 μM) demonstrated a moderated non-significant decrease in cell viability” should be re-written. If you have conducted statistics to show a trend then indicate the P value of the trend. A non significant difference means that there is no difference between the groups.

Page 17, Glucose (25 ,50 ,100 μM) – reposition the commas after the numbers to (25, 50,100 μM)

One missing set of experiments is that the drug incubations should also have been completed on insulin treated myotubes. That would paint a more complete picture of the effects of these drug concentrations on myotube glucose handling as a whole.

Reviewer #2: Through evaluating the intracellular mechanisms leading to the development of insulin resistance in the presence of various conventional pharmacological agents reported as potential mitochondrial toxicants in skeletal muscle cell line, the authors deciphered the effect of drug-induced mitochondrial dysfunction on insulin signalling cascade and glucose handling in C2C12 cell line in vitro. They used differentiated C2C12 preparations to be exposed to various concentrations of efavirenz, tenofovir, rifampicin, simvastatin, lamotrigine, and clarithromycin, separately, and then observed and measured the effect of drug-induced mitochondrial dysfunction on insulin signalling cascade. And they finally argued that the mitochondrial toxicants could potentially induce insulin resistance emanating from mitochondrial dysfunction. However, as indicated by the authors, the potential mitochondrial toxicants, efavirenz, tenofovir, rifampicin, simvastatin, lamotrigine, and clarithromycin have their own specific effects on insulin signalling cascade. Why is the same observation and measurement performed for all the mitochondrial toxicants?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0310406.r002
Author response to Decision Letter 0
Submission Version1
10 Aug 2024

Reviewer #1: GENERAL COMMENTS

The study tested the effects of several compounds to alter mitochondrial function and induce insulin resistance. There were some English/grammar issues that a thorough re-read can fix. Although the approaches were appropriate and the data appeared to be carefully obtained, the significant issue was that the drug studies were not completed on insulin treated myotubes.

We thank the reviewer for the comments.

We have substantively revised the manuscript for English and Grammatical issues.

. Our goal aimed to understand how exposure of cells to mitotoxic agents could lessen insulin’ effects. Hence our approach aimed to pre-treat the cells with these mitotoxic drugs, followed by insulin treatment. In this way, we could be able to observe changes in insulin sensitivity post-exposure to mitotoxic agents such as glucose uptake and GLUT4 translocation. We believe through this approach, we have been able in part to prove that drug-induced mitochondrial dysfunction (using 6 separate classes of drugs) does affect insulin sensitivity as evidenced by a decrease in insulin-stimulated glucose uptake, AKT, and GLUT 4 translocation. We believe the experiment proposed by a reviewer could be a significant stand-alone study, as it is a different approach, considering that the cells would be pre-treated with insulin following by mitotoxic agents. As such, preliminary experiments will also be vital to establish time-points where one can observe the effects. We welcome the reviewer’s comment, however from what we have outline above together with logistical issues associated studies of this nature, we believe this can be conducted as a follow-up study. We would like to believe the current observation broadly shed light on the effect of mitochondrial dysfunction on insulin effect.

SPECIFIC COMMENTS

Page 17, Results, line 6-7. The sentence “However, efavirenz, lamotrigine and rifampicin (100 μM) demonstrated a moderated non-significant decrease in cell viability” should be re-written. If you have conducted statistics to show a trend then indicate the P value of the trend. A non significant difference means that there is no difference between the groups.

We thank the reviewer for this comment, this has been attended to as suggested

Page 17, Glucose (25 ,50 ,100 μM) – reposition the commas after the numbers to (25, 50,100 μM)

We thank the reviewer for this comment this has been fixed

One missing set of experiments is that the drug incubations should also have been completed on insulin treated myotubes. That would paint a more complete picture of the effects of these drug concentrations on myotube glucose handling as a whole.

We thank the reviewer for this insightful comment. The goal for this study was to broadly demonstrate how mitochondrial dysfunction through drugs affects insulin signalling pathway and glucose handling. Hence we aimed to understand how pre-exposure of cells to mitotoxic agents could lessen insulin effects. Our approach therefore aimed to pre-treat the cells with these mitotoxic drugs, followed by insulin treatment, after which measurements of parameters were conducted. In this way, we could be able to observe changes in insulin sensitivity post-exposure to mitotoxic agents. We believe through this approach, we have been able in part to prove that drug-induced mitochondrial dysfunction (using 6 different classes of drugs) does affect insulin sensitivity as evidenced by a decrease in insulin-stimulated glucose uptake, AKT, and GLUT 4 translocation. We believe the experiment proposed by a reviewer could be a significant stand-alone study, as it is a different approach, considering that the cells would be pre-treated with insulin, following by mitotoxic agents. As such, preliminary experiments will also be vital to establish time-points where one can observe the effects. We welcome the reviewer’s comment, however from what we have outline above together with logistical issues associated studies of this nature, we believe this can be conducted as a follow-up study.

Reviewer #2: Through evaluating the intracellular mechanisms leading to the development of insulin resistance in the presence of various conventional pharmacological agents reported as potential mitochondrial toxicants in skeletal muscle cell line, the authors deciphered the effect of drug-induced mitochondrial dysfunction on insulin signalling cascade and glucose handling in C2C12 cell line in vitro. They used differentiated C2C12 preparations to be exposed to various concentrations of efavirenz, tenofovir, rifampicin, simvastatin, lamotrigine, and clarithromycin, separately, and then observed and measured the effect of drug-induced mitochondrial dysfunction on insulin signalling cascade. And they finally argued that the mitochondrial toxicants could potentially induce insulin resistance emanating from mitochondrial dysfunction. However, as indicated by the authors, the potential mitochondrial toxicants, efavirenz, tenofovir, rifampicin, simvastatin, lamotrigine, and clarithromycin have their own specific effects on insulin signalling cascade. Why is the same observation and measurement performed for all the mitochondrial toxicants?

We thank the reviewer for this insightful and interesting comment. Indeed, these agents could affect glucose metabolism through other affected pathways. However, what they have in common is disturbance in mitochondrial dysfunction. Although similar observations were reported, however, the extent on the effect was not the same, as some were more robust than others in affecting glucose handling and insulin signalling pathway. The same measurement was reported for the sake of uniformity and drawing comparison. The goal for now was to broadly demonstrate how mitochondrial dysfunction through commonly prescribed drugs affects insulin signalling pathway and glucose handling, therefore pose a risk of insulin resistance onset. We however believe this is a crucial point to take forward as we aim to further refine possible mechanisms utilized by these agents to alter glucose handling.

Attachment Submitted filename: Plos One Rebuttal letter.pdf

10.1371/journal.pone.0310406.r003
Decision Letter 1
Kanzaki Makoto Academic Editor
© 2024 Makoto Kanzaki
2024
Makoto Kanzaki
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version1
2 Sep 2024

Elucidating the effect of drug-induced mitochondrial dysfunction on insulin signaling and glucose handling in skeletal muscle cell line (C2C12) in vitro

PONE-D-24-02153R1

Dear Dr. Sibiya,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Makoto Kanzaki, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Congratulations!

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The concerns have been addressed. The only thing remaining is improving the image quality of the figures.

Figures 1 and 2, 7,9 and 11 had a pink background color that should be removed so that the background is white like the other figures.

Figure 11 has a low image quality and I could not read the words on the figure.

Reviewer #2: The authors addressed my raised comments. They also performed some needed revisions. No more comments.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

10.1371/journal.pone.0310406.r004
Acceptance letter
Kanzaki Makoto Academic Editor
© 2024 Makoto Kanzaki
2024
Makoto Kanzaki
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
4 Sep 2024

PONE-D-24-02153R1

PLOS ONE

Dear Dr. Sibiya,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Makoto Kanzaki

Academic Editor

PLOS ONE
==== Refs
References

1 Wu Y , Ding Y , Tanaka Y , Zhang W . Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention. Int J Med Sci. 2014 Sep 6;11 (11 ):1185–200. doi: 10.7150/ijms.10001 25249787
2 Saeedi P , Petersohn I , Salpea P , Malanda B , Karuranga S , Unwin N , et al . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov 1;157 :107843. doi: 10.1016/j.diabres.2019.107843 31518657
3 Williams R , Karuranga S , Malanda B , Saeedi P , Basit A , Besançon S , et al . Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020 Apr;162 :108072. doi: 10.1016/j.diabres.2020.108072 32061820
4 Freeman AM, Acevedo LA, Pennings N. Insulin Resistance. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Jan 13]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK507839/
5 Galicia-Garcia U , Benito-Vicente A , Jebari S , Larrea-Sebal A , Siddiqi H , Uribe KB , et al . Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21 (17 ):6275. doi: 10.3390/ijms21176275 32872570
6 Rehman K , Akash MSH . Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci. 2016 Dec 3;23 (1 ):87. doi: 10.1186/s12929-016-0303-y 27912756
7 Li M , Chi X , Wang Y , Setrerrahmane S , Xie W , Xu H . Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022 Jul 6;7 (1 ):1–25.34980881
8 Wilcox G. Insulin and Insulin Resistance. Clin Biochem Rev. 2005 May;26(2):19–39.
9 Kim J a, Wei Y, Sowers JR. Role of Mitochondrial Dysfunction in Insulin Resistance. Circ Res. 2008 Feb 29;102(4):401–14.
10 Sergi D , Naumovski N , Heilbronn LK , Abeywardena M , O’Callaghan N , Lionetti L , et al . Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet. Front Physiol [Internet]. 2019 [cited 2024 Jan 13];10. Available from: https://www.frontiersin.org/articles/10.3389/fphys.2019.00532
11 Sangwung P , Petersen KF , Shulman GI , Knowles JW . Mitochondrial Dysfunction, Insulin Resistance, and Potential Genetic Implications. Endocrinology. 2020 Feb 15;161 (4 ):bqaa017. doi: 10.1210/endocr/bqaa017 32060542
12 Supinski GS , Schroder EA , Callahan LA . Mitochondria and Critical Illness. Chest. 2020 Feb;157 (2 ):310–22. doi: 10.1016/j.chest.2019.08.2182 31494084
13 Missiroli S , Genovese I , Perrone M , Vezzani B , Vitto VAM , Giorgi C . The Role of Mitochondria in Inflammation: From Cancer to Neurodegenerative Disorders. J Clin Med. 2020 Mar 9;9 (3 ):740. doi: 10.3390/jcm9030740 32182899
14 Patti ME , Corvera S . The Role of Mitochondria in the Pathogenesis of Type 2 Diabetes. Endocr Rev. 2010 Jun;31 (3 ):364–95. doi: 10.1210/er.2009-0027 20156986
15 Kuretu A , Arineitwe C , Mothibe M , Ngubane P , Khathi A , Sibiya N . Drug-induced mitochondrial toxicity: Risks of developing glucose handling impairments. Front Endocrinol [Internet]. 2023 [cited 2024 Jan 13];14. Available from: https://www.frontiersin.org/articles/10.3389/fendo.2023.1123928 doi: 10.3389/fendo.2023.1123928 36860368
16 Merz KE , Thurmond DC . Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. Compr Physiol. 2020 Jul 8;10 (3 ):785–809. doi: 10.1002/cphy.c190029 32940941
17 Turcotte LP , Fisher JS . Skeletal Muscle Insulin Resistance: Roles of Fatty Acid Metabolism and Exercise. Phys Ther. 2008 Nov;88 (11 ):1279–96. doi: 10.2522/ptj.20080018 18801860
18 Sylow L , Tokarz VL , Richter EA , Klip A . The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metab. 2021 Apr 6;33 (4 ):758–80. doi: 10.1016/j.cmet.2021.03.020 33826918
19 Lin YT , Lin KH , Huang CJ , Wei AC . MitoTox: a comprehensive mitochondrial toxicity database. BMC Bioinformatics. 2021 Jul 15;22 (10 ):369. doi: 10.1186/s12859-021-04285-3 34266386
20 Potter T , Neun B , Stern S . Assay to Detect Lipid Peroxidation upon Exposure to Nanoparticles. Methods Mol Biol Clifton NJ. 2011 Jan 1;697 :181–9. doi: 10.1007/978-1-60327-198-1_19 21116967
21 Yudhani RD , Sari Y , Nugrahaningsih DAA , Sholikhah EN , Rochmanti M , Purba AKR , et al . In Vitro Insulin Resistance Model: A Recent Update. J Obes. 2023;2023 :1964732. doi: 10.1155/2023/1964732 36714242
22 Wasserman DH . Insulin, Muscle Glucose Uptake, and Hexokinase: Revisiting the Road Not Taken. Physiology. 2022 May 1;37 (3 ):115–27. doi: 10.1152/physiol.00034.2021 34779282
23 Świderska E , Strycharz J , Wróblewski A , Szemraj J , Drzewoski J , Śliwińska A , et al . Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake. In: Blood Glucose Levels [Internet]. IntechOpen; 2018 [cited 2024 Jan 13]. Available from: https://www.intechopen.com/chapters/63301
24 Sinxadi PZ , McIlleron HM , Dave JA , Smith PJ , Levitt NS , Haas DW , et al . Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations. Medicine (Baltimore). 2016 Jan 15;95 (2 ):e2385. doi: 10.1097/MD.0000000000002385 26765416
25 Gwag T , Meng Z , Sui Y , Helsley RN , Park SH , Wang S , et al . Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis. J Hepatol. 2019 May;70 (5 ):930–40. doi: 10.1016/j.jhep.2018.12.038 30677459
26 Meintjes G , Black J , Conradie F , Cox V , Dlamini S , Fabian J , et al . Adult antiretroviral therapy guidelines 2014.
27 Apostolova N , Funes HA , Blas-Garcia A , Galindo MJ , Alvarez A , Esplugues JV . Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother. 2015 Oct 1;70 (10 ):2693–708. doi: 10.1093/jac/dkv183 26203180
28 Blas-García A , Apostolova N , Ballesteros D , Monleón D , Morales JM , Rocha M , et al . Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology. 2010;52 (1 ):115–25. doi: 10.1002/hep.23647 20564379
29 Margolis AM , Heverling H , Pham PA , Stolbach A . A Review of the Toxicity of HIV Medications. J Med Toxicol. 2014 Mar;10 (1 ):26–39. doi: 10.1007/s13181-013-0325-8 23963694
30 Anderson EJ , Lustig ME , Boyle KE , Woodlief TL , Kane DA , Lin CT , et al . Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009 Mar;119 (3 ):573–81. doi: 10.1172/JCI37048 19188683
31 Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns | Drug Safety [Internet]. [cited 2024 Jan 13]. Available from: https://link.springer.com/article/10.1007/s40264-017-0505-6
32 Pilkington V , Hill A , Hughes S , Nwokolo N , Pozniak A . How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J Virus Erad. 4 (4 ):215–24. doi: 10.1056/NEJMoa1108524 30515300
33 Glidden DV , Mulligan K , McMahan V , Anderson PL , Guanira J , Chariyalertsak S , et al . Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis. 2018 Jul 18;67 (3 ):411–9. doi: 10.1093/cid/ciy083 29415175
34 Birkus G , Hitchcock MJM , Cihlar T . Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors. Antimicrob Agents Chemother. 2002 Mar;46 (3 ):716–23. doi: 10.1128/AAC.46.3.716-723.2002 11850253
35 Kohler JJ , Hosseini SH , Hoying-Brandt A , Green E , Johnson DM , Russ R , et al . Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Investig J Tech Methods Pathol. 2009 May;89 (5 ):513–9. doi: 10.1038/labinvest.2009.14 19274046
36 Perazella MA . Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int. 2010 Dec;78 (11 ):1060–3. doi: 10.1038/ki.2010.344 21076445
37 Schlame M , Xu Y . The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase. J Mol Biol. 2020 Aug 21;432 (18 ):5043–51. doi: 10.1016/j.jmb.2020.03.026 32234310
38 Acehan D , Malhotra A , Xu Y , Ren M , Stokes DL , Schlame M . Cardiolipin Affects the Supramolecular Organization of ATP Synthase in Mitochondria. Biophys J. 2011 May 5;100 (9 ):2184. doi: 10.1016/j.bpj.2011.03.031 21539786
39 Pfeiffer K , Gohil V , Stuart RA , Hunte C , Brandt U , Greenberg ML , et al . Cardiolipin Stabilizes Respiratory Chain Supercomplexes. J Biol Chem. 2003 Dec;278 (52 ):52873–80. doi: 10.1074/jbc.M308366200 14561769
40 Brandner K , Mick DU , Frazier AE , Taylor RD , Meisinger C , Rehling P . Taz1, an Outer Mitochondrial Membrane Protein, Affects Stability and Assembly of Inner Membrane Protein Complexes: Implications for Barth Syndrome. Mol Biol Cell. 2005 Nov;16 (11 ):5202–14. doi: 10.1091/mbc.e05-03-0256 16135531
41 Mileykovskaya E , Dowhan W . Cardiolipin-Dependent Formation of Mitochondrial Respiratory Supercomplexes. Chem Phys Lipids. 2014 Apr;179 :42–8. doi: 10.1016/j.chemphyslip.2013.10.012 24220496
42 Chen S , He Q , Greenberg ML . Loss of tafazzin in yeast leads to increased oxidative stress during respiratory growth. Mol Microbiol. 2008 May;68 (4 ):1061–72. doi: 10.1111/j.1365-2958.2008.06216.x 18430085
43 Makaryan V , Kulik W , Vaz FM , Allen C , Dror Y , Dale DC , et al . The cellular and molecular mechanisms for neutropenia in Barth syndrome. Eur J Haematol. 2012 Mar;88 (3 ):195–209. doi: 10.1111/j.1600-0609.2011.01725.x 22023389
44 Prasad R , Gupta N , Banka A . Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management. Lung India Off Organ Indian Chest Soc. 2018;35 (1 ):78–81. doi: 10.4103/lungindia.lungindia_98_17 29319042
45 Garg A , Alam M , Bai S , Dandawate M , Kumari N , Gupta S , et al . Protective Effects of Rifampicin and Its Analog Rifampicin Quinone in a Mouse Model of Obesity-Induced Type 2 Diabetes. ACS Pharmacol Transl Sci. 2023 Feb 10;6 (2 ):253–69. doi: 10.1021/acsptsci.2c00082 36798477
46 Lee EH , Baek SY , Park JY , Kim YW . Rifampicin activates AMPK and alleviates oxidative stress in the liver as mediated with Nrf2 signaling. Chem Biol Interact. 2020 Jan 5;315 :108889. doi: 10.1016/j.cbi.2019.108889 31678598
47 Liang Y , Zhou T , Chen Y , Lin D , Jing X , Peng S , et al . Rifampicin inhibits rotenone-induced microglial inflammation via enhancement of autophagy. NeuroToxicology. 2017 Dec 1;63 :137–45. doi: 10.1016/j.neuro.2017.09.015 28986232
48 Li F , Zhou J , Li Y , Sun K , Chen J . Mitochondrial Damage and Drp1 Overexpression in Rifampicin- and Isoniazid-induced Liver Injury Cell Model. J Clin Transl Hepatol. 2019 Mar 28;7 (1 ):40–5. doi: 10.14218/JCTH.2018.00052 30944818
49 Chowdhury A , Santra A , Bhattacharjee K , Ghatak S , Saha DR , Dhali GK . Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol. 2006 Jul;45 (1 ):117–26. doi: 10.1016/j.jhep.2006.01.027 16545483
50 Enriquez-Cortina C , Almonte-Becerril M , Clavijo-Cornejo D , Palestino-Domínguez M , Bello-Monroy O , Nuño N , et al . Hepatocyte Growth Factor Protects Against Isoniazid/Rifampicin-Induced Oxidative Liver Damage. Toxicol Sci. 2013 Sep 1;135 (1 ):26–36. doi: 10.1093/toxsci/kft134 23764483
51 Erokhina MV , Kurynina AV , Onishchenko GE . Mitochondria are targets for the antituberculosis drug rifampicin in cultured epithelial cells. Biochem Biokhimiia. 2013 Oct;78 (10 ):1155–63. doi: 10.1134/S0006297913100106 24237150
52 Patel PH, Hashmi MF. Macrolides. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Jan 14]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK551495/
53 Vázquez-Laslop N , Mankin AS . How macrolide antibiotics work. Trends Biochem Sci. 2018 Sep;43 (9 ):668–84. doi: 10.1016/j.tibs.2018.06.011 30054232
54 Evans JL , Goldfine ID , Maddux BA , Grodsky GM . Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002 Oct;23 (5 ):599–622. doi: 10.1210/er.2001-0039 12372842
55 Chandel NS , McClintock DS , Feliciano CE , Wood TM , Melendez JA , Rodriguez AM , et al . Reactive Oxygen Species Generated at Mitochondrial Complex III Stabilize Hypoxia-inducible Factor-1α during Hypoxia: A MECHANISM OF O2 SENSING*. J Biol Chem. 2000 Aug 18;275 (33 ):25130–8.10833514
56 Chen Q , Vazquez EJ , Moghaddas S , Hoppel CL , Lesnefsky EJ . Production of Reactive Oxygen Species by Mitochondria: CENTRAL ROLE OF COMPLEX III*. J Biol Chem. 2003 Sep 19;278 (38 ):36027–31. doi: 10.1074/jbc.M304854200 12840017
57 Zorov DB , Juhaszova M , Sollott SJ . Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release. Physiol Rev. 2014 Jul;94 (3 ):909–50. doi: 10.1152/physrev.00026.2013 24987008
58 Holt RIG . Association Between Antipsychotic Medication Use and Diabetes. Curr Diab Rep. 2019;19 (10 ):96. doi: 10.1007/s11892-019-1220-8 31478094
59 Chen J , Huang XF , Shao R , Chen C , Deng C . Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes. Front Neurosci. 2017 Nov 21;11 :643. doi: 10.3389/fnins.2017.00643 29209160
60 Nagashima T , Shirakawa H , Nakagawa T , Kaneko S . Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism. Sci Rep. 2016 May 20;6 :26375. doi: 10.1038/srep26375 27199286
61 Ho E , Karimi Galougahi K , Liu CC , Bhindi R , Figtree GA . Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol. 2013 Jan 1;1 (1 ):483–91. doi: 10.1016/j.redox.2013.07.006 24251116
62 Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal ‐ PMC [Internet]. [cited 2024 Jan 14]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066722/
63 Houstis N , Rosen ED , Lander ES . Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006 Apr;440 (7086 ):944–8. doi: 10.1038/nature04634 16612386
64 Abbasi F , Lamendola C , Harris CS , Harris V , Tsai MS , Tripathi P , et al . Statins Are Associated With Increased Insulin Resistance and Secretion. Arterioscler Thromb Vasc Biol. 2021 Nov;41 (11 ):2786–97. doi: 10.1161/ATVBAHA.121.316159 34433298
65 Cederberg H , Stančáková A , Yaluri N , Modi S , Kuusisto J , Laakso M . Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015 May 1;58 (5 ):1109–17. doi: 10.1007/s00125-015-3528-5 25754552
66 Szendroedi J , Anderwald C , Krssak M , Bayerle-Eder M , Esterbauer H , Pfeiler G , et al . Effects of High-Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Nonobese Type 2 Diabetic Patients. Diabetes Care. 2009 Feb;32 (2 ):209–14. doi: 10.2337/dc08-1123 18957532
67 Larsen S , Stride N , Hey-Mogensen M , Hansen CN , Bang LE , Bundgaard H , et al . Simvastatin Effects on Skeletal Muscle: Relation to Decreased Mitochondrial Function and Glucose Intolerance. J Am Coll Cardiol. 2013 Jan 8;61 (1 ):44–53. doi: 10.1016/j.jacc.2012.09.036 23287371
68 Mollazadeh H , Tavana E , Fanni G , Bo S , Banach M , Pirro M , et al . Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021 Apr;12 (2 ):237–51. doi: 10.1002/jcsm.12654 33511728
69 Deichmann R , Lavie C , Andrews S . Coenzyme Q10 and Statin-Induced Mitochondrial Dysfunction. Ochsner J. 2010 Spring;10 (1 ):16. 21603349
70 Marcoff L , Thompson PD . The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review. J Am Coll Cardiol. 2007 Jun 12;49 (23 ):2231–7. doi: 10.1016/j.jacc.2007.02.049 17560286
71 Zorova LD , Popkov VA , Plotnikov EY , Silachev DN , Pevzner IB , Jankauskas SS , et al . Mitochondrial membrane potential. Anal Biochem. 2018 Jul 1;552 :50–9. doi: 10.1016/j.ab.2017.07.009 28711444
72 Jones SP , Teshima Y , Akao M , Marbán E . Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res. 2003 Oct 17;93 (8 ):697–9. doi: 10.1161/01.RES.0000097262.21507.DF 14512440
73 Ridker PM , Pradhan A , MacFadyen JG , Libby P , Glynn RJ . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet Lond Engl. 2012 Aug 11;380 (9841 ):565–71. doi: 10.1016/S0140-6736(12)61190-8 22883507
74 Gholobova D , Gerard M , Decroix L , Desender L , Callewaert N , Annaert P , et al . Human tissue-engineered skeletal muscle: a novel 3D in vitro model for drug disposition and toxicity after intramuscular injection. Sci Rep. 2018 Aug 15;8 (1 ):12206. doi: 10.1038/s41598-018-30123-3 30111779
75 Cittadella Vigodarzere G , Mantero S . Skeletal muscle tissue engineering: strategies for volumetric constructs. Front Physiol [Internet]. 2014 [cited 2024 Jan 14];5. Available from: https://www.frontiersin.org/articles/10.3389/fphys.2014.00362 doi: 10.3389/fphys.2014.00362 25295011
76 Jiang Y , Torun T , Maffioletti SM , Serio A , Tedesco FS . Bioengineering human skeletal muscle models: Recent advances, current challenges and future perspectives. Exp Cell Res. 2022 Jul 15;416 (2 ):113133. doi: 10.1016/j.yexcr.2022.113133 35427601
77 Jalal S , Dastidar S , Tedesco FS . Advanced models of human skeletal muscle differentiation, development and disease: Three-dimensional cultures, organoids and beyond. Curr Opin Cell Biol. 2021 Dec;73 :92–104. doi: 10.1016/j.ceb.2021.06.004 34384976
